BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 9781603)

  • 1. A phase II study of high-dose cimetidine and the combination 5-fluorouracil, interferon alpha-2A, and leucovorin in advanced renal cell adenocarcinoma.
    Creagan ET; Veeder MH; Suman VJ; Burch PA; Maples WJ; Schaefer PL; Pfeifle DM; Dalton RJ; Hatfield AK; Poon MA
    Am J Clin Oncol; 1998 Oct; 21(5):475-8. PubMed ID: 9781603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of 5-fluorouracil and leucovorin in combination with interferon-alpha and interleukin-2 for advanced renal cell cancer.
    Rathmell WK; Malkowicz SB; Holroyde C; Luginbuhl W; Vaughn DJ
    Am J Clin Oncol; 2004 Apr; 27(2):109-12. PubMed ID: 15057147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-Fluorouracil/leucovorin/interferon alpha-2a in patients with advanced colorectal cancer. Effects of maintenance therapy on remission duration.
    Buter J; Sinnige HA; Sleijfer DT; de Vries EG; Willemse PH; van der Graaf WT; Verschueren RC; Mulder NH
    Cancer; 1995 Mar; 75(5):1072-6. PubMed ID: 7850703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bimonthly high dose leucovorin and 5-fluorouracil 48-hour infusion with interferon-alpha-2a in patients with advanced colorectal carcinoma. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD).
    Tournigand C; Louvet C; de Gramont A; Lucchi E; Seitz JF; Mal F; Raymond E; Cady J; Carola E; Krulik M
    Cancer; 1997 Mar; 79(6):1094-9. PubMed ID: 9070485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma.
    Ilson DH; Sirott M; Saltz L; Heelan R; Huang Y; Keresztes R; Kelsen DP
    Cancer; 1995 May; 75(9):2197-202. PubMed ID: 7712428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I-II study of the addition of alpha-2a interferon to 5-fluorouracil/leucovorin. Pharmacokinetic interaction of alpha-2a interferon and leucovorin.
    Sinnige HA; Buter J; de Vries EG; Uges DR; Roenhorst HW; Verschueren RC; Sleijfer DT; Willemse PH; Mulder NH
    Eur J Cancer; 1993; 29A(12):1715-20. PubMed ID: 8398300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administration Propeukin Program Cooperative Group.
    Tourani JM; Pfister C; Berdah JF; Benhammouda A; Salze P; Monnier A; Paule B; Guillet P; Chretien Y; Brewer Y; Di Palma M; Untereiner M; Malaurie E; Tadrist Z; Pavlovitch JM; Hauteville D; Mejean A; Azagury M; Mayeur D; Lucas V; Krakowski I; Larregain-Fournier D; Abourachid H; Andrieu JM; Chastang C
    J Clin Oncol; 1998 Jul; 16(7):2505-13. PubMed ID: 9667271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin.
    Fleming GF; O'Brien SM; Hoffman PC; Vokes EE; Vogelzang NJ; Schilsky RL; Waggoner SE; Ratain MJ
    Cancer Chemother Pharmacol; 1997; 39(3):227-32. PubMed ID: 8996525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pilot study of interferon alpha-2a, fluorouracil, and leucovorin given with granulocyte-macrophage colony stimulating factor in advanced gastrointestinal adenocarcinoma.
    Shapiro JD; Harold N; Takimoto C; Hamilton JM; Vaughn D; Chen A; Steinberg SM; Liewehr D; Allegra C; Monahan B; Lash A; Grollman F; Flemming D; Behan K; Johnston PG; Haller D; Quinn M; Morrison G; Grem JL
    Clin Cancer Res; 1999 Sep; 5(9):2399-408. PubMed ID: 10499610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. Corfu-A Study Group.
    J Clin Oncol; 1995 Apr; 13(4):921-8. PubMed ID: 7707120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of fluorouracil, leucovorin, and interferon alfa-2a in metastatic colorectal carcinoma.
    Grem JL; Jordan E; Robson ME; Binder RA; Hamilton JM; Steinberg SM; Arbuck SG; Beveridge RA; Kales AN; Miller JA
    J Clin Oncol; 1993 Sep; 11(9):1737-45. PubMed ID: 8355041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infusional interleukin-2 and 5-fluorouracil with subcutaneous interferon-alpha for the treatment of patients with advanced renal cell carcinoma: a southwest oncology group Phase II study.
    Elias L; Lew D; Figlin RA; Flanigan RC; Thompson ME; Triozzi PL; Belt RJ; Wood DP; Rivkin SE; David E
    Cancer; 2000 Aug; 89(3):597-603. PubMed ID: 10931459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I trial of 5-fluorouracil, folinic acid, and alpha-2a-interferon in patients with metastatic colorectal carcinoma.
    Bukowski RM; Inoshita G; Yalavarthi P; Murthy S; Gibson V; Budd GT; Sergi JS; Bauer L; Prestifilippo J
    Cancer; 1992 Feb; 69(4):889-92. PubMed ID: 1735080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma.
    Grem JL; McAtee N; Murphy RF; Balis FM; Steinberg SM; Hamilton JM; Sorensen JM; Sartor O; Kramer BS; Goldstein LJ
    J Clin Oncol; 1991 Oct; 9(10):1811-20. PubMed ID: 1919632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of 5-fluorouracil, leucovorin and interferon-alpha in advanced pancreatic cancer.
    Moore MJ; Erlichman C; Kaizer L; Fine S
    Anticancer Drugs; 1993 Oct; 4(5):555-7. PubMed ID: 8292812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II trial of etoposide, leucovorin, 5-FU, and interferon alpha 2b (ELFI) + G-CSF for patients with pancreatic adenocarcinoma: a Southwest Oncology Group study (SWOG 9413).
    Macdonald JS; Jacobson JL; Modiano M; Moore DF; Gandara DR; Schroder LE; Chapman RA
    Invest New Drugs; 2000 Aug; 18(3):269-73. PubMed ID: 10958597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of advanced pancreatic cancer with 5-fluorouracil, folinic acid and interferon alpha-2A: results of a phase II trial.
    Bernhard H; Jäger-Arand E; Bernhard G; Heike M; Klein O; Riemann JF; Meyer zum Büschenfelde KH; Dippold W; Knuth A
    Br J Cancer; 1995 Jan; 71(1):102-5. PubMed ID: 7819023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II trial of interferon-alpha and 5-fluorouracil in patients with advanced renal cell carcinoma. A Southwest Oncology Group study.
    Elias L; Blumenstein BA; Kish J; Flanigan RC; Wade JL; Lowe BA; Goodwin JW; Crawford ED
    Cancer; 1996 Sep; 78(5):1085-8. PubMed ID: 8780547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluorouracil plus interferon + folinic acid in regional and systemic therapy in colorectal cancer.
    Preiss J
    Semin Oncol; 1992 Apr; 19(2 Suppl 3):220-4. PubMed ID: 1557652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Impact of immunochemotherapy on survival of patients with metastatic renal cell carcinoma. A retrospective study comparing interferon-alpha-2a/vinblastine versus interferon-alpha-2a/interleukin-2/5-fluorouracil].
    May M; Helke C; Bock M; Hoschke B
    Urologe A; 2004 Sep; 43(9):1111-9. PubMed ID: 15232686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.